Clinical efficacy of Daikenchuto (DKT: TJ-100) for gastrointestinal dysfunction following colon surgery (a randomized, double-blind, multi-center, placebo-controlled study) Additional study:Gastrointestinal transit time as an indicator
Phase 3
Completed
- Conditions
- Colon cancer (Sigmoidal and Rectosigmoidal regions)
- Registration Number
- JPRN-UMIN000001793
- Lead Sponsor
- Japanese Foundation for Multidisciplinary Treatment of Cancer
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
1)Participate in JFMC39-0902
2)Amenable to curative resection in colon cancer (Sigmoidal and Rectosigmoidal regions)
3)Patients who can provide written informed consent
Exclusion Criteria
1)Patients who are unfit for the study as determined by the attending physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Daikenchuto's effects on postoperative gastrointestinal motility in colon cancer patients?
How does Daikenchuto compare to standard-of-care therapies for post-colon surgery gastrointestinal dysfunction in phase III trials?
Are there specific biomarkers that predict response to Daikenchuto in patients with sigmoidal or rectosigmoidal colon cancer?
What are the known adverse events associated with Daikenchuto use in postoperative colon cancer patients and how are they managed?
What combination therapies or alternative herbal compounds show promise in treating postoperative gastrointestinal dysfunction in colon cancer patients?